The roles of the sympathetic nervous system in osteoporotic diseases: A review of experimental and clinical studies

Ageing Research Reviews

Volumn 10, Issue 2, 2011, Pages 253-263

  He, Ji Ye ^a   Jiang, Lei Sheng ^a   Dai, Li Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adrenergic signaling; Bone remodeling; Neurotransmitter; Osteoporotic disease; Sympathetic nervous system

Indexed keywords

LEPTIN;

ADRENERGIC TRANSMISSION; BONE METABOLISM; BONE REMODELING; CLINICAL STUDY; COMPLEX REGIONAL PAIN SYNDROME; DEPRESSION; DISEASE ASSOCIATION; EXPERIMENTAL STUDY; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; OSTEOPOROSIS; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SYMPATHETIC INNERVATION;

BONE AND BONES; BONE REMODELING; FEMALE; HUMANS; HYPOTHALAMUS; MENOPAUSE; OSTEOPOROSIS; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 79952441210     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2011.01.002     Document Type: Review

References (144)

1. Adami S., Fossaluzza V., Gatti D., Fracassi E., Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann. Rheum. Dis. 1997, 56:201-204.
2. Ahima R.S., Flier J.S. Leptin. Annu. Rev. Physiol. 2000, 62:413-437.
3. Akune T., Ogata N., Hoshi K., Kubota N., Terauchi Y., Tobe K., Takagi H., Azuma Y., Kadowaki T., Nakamura K., Kawaguchi H. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J. Cell Biol. 2002, 159:147-156.
4. Albrecht P.J., Hines S., Eisenberg E., Pud D., Finlay D.R., Connolly M.K., Pare M., Davar G., Rice F.L. Pathologic alterations of cutaneous innervation and vasculature in affected limbs from patients with complex regional pain syndrome. Pain 2006, 120:244-266.
5. Alesci S., Martinez P.E., Kelkar S., Ilias I., Ronsaville D.S., Listwak S.J., Ayala A.R., Licinio J., Gold H.K., Kling M.A., Chrousos G.P., Gold P.W. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 2005, 90:2522-2530.
6. Ali Z., Raja S.N., Wesselmann U., Fuchs P.N., Meyer R.A., Campbell J.N. Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain. Pain 2000, 88:161-168.
7. Altindag O., Altindag A., Asoglu M., Gunes M., Soran N., Deveci Z. Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 2007, 61:416-420.
8. Asmus S.E., Parsons S., Landis S.C. Developmental changes in the transmitter properties of sympathetic neurons that innervate the periosteum. J. Neurosci. 2000, 20:1495-1504.
9. Azpiroz A., Fano E., Garmendia L., Arregi A., Cacho R., Beitia G., Brain P.F. Effects of chronic mild stress (CMS) and imipramine administration, on spleen mononuclear cell proliferative response, serum corticosterone level and brain norepinephrine content in male mice. Psychoneuroendocrinology 1999, 24:345-361.
10. Bab I.A., Yirmiya R. Depression and bone mass. Ann. N. Y. Acad. Sci. 2010, 1192:170-175.
11. Baek K., Bloomfield S.A. β-Adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J. Bone Miner. Res. 2009, 24:792-799.
12. Bajayo A., Goshen I., Feldman S., Csernus V., Iverfeldt K., Shohami E., Yirmiya R., Bab I. Central IL-1 receptor signaling regulates bone growth and mass. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12956-12961.
13. Basso N., Heersche J.N. Effects of hind limb unloading and reloading on nitric oxide synthase expression and apoptosis of osteocytes and chondrocytes. Bone 2006, 39:807-814.
14. Blazer D.G., Kessler R.C., McGonagle K.A., Swartz M.S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 1994, 151:979-986.
15. Bliziotes M.M., Eshleman A.J., Zhang X.W., Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001, 29:477-486.
16. Bloomfield S.A. Changes in musculoskeletal structure and function with prolonged bed rest. Med. Sci. Sports Exerc. 1997, 29:197-206.
17. Bonnet N., Benhamou C.L., Brunet-Imbault B., Arlettaz A., Horcajada M.N., Richard O., Vico L., Collomp K., Courteix D. Severe bone alterations under β2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 2005, 37:622-633.
18. Bonnet N., Benhamou C.L., Malaval L., Goncalves C., Vico L., Eder V., Pichon C., Courteix D. Low dose β-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J. Cell. Physiol. 2008, 217:819-827.
19. Bonnet N., Gadois C., McCloskey E., Lemineur G., Lespessailles E., Courteix D., Benhamou C.L. Protective effect of β blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007, 40:1209-1216.
20. Bonnet N., Laroche N., Vico L., Dolleans E., Benhamou C.L., Courteix D. Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J. Pharmacol. Exp. Ther. 2006, 318:1118-1127.
21. Bouxsein M.L., Devlin M.J., Glatt V., Dhillon H., Pierroz D.D., Ferrari S.L. Mice lacking β-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology 2009, 150:144-152.
22. Boyce B.F., Schwarz E.M., Xing L. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr. Opin. Rheumatol. 2006, 18:427-432.
23. Breuer B., Pappagallo M., Ongseng F., Chen C.I., Goldfarb R. An open-label pilot trial of ibandronate for complex regional pain syndrome. Clin. J. Pain 2008, 24:685-689.
24. Burr D.B., Robling A.G., Turner C.H. Effects of biomechanical stress on bones in animals. Bone 2002, 30:781-786.
25. Burt-Pichat B., Lafage-Proust M.H., Duboeuf F., Laroche N., Itzstein C., Vico L., Delmas P.D., Chenu C. Dramatic decrease of innervation density in bone after ovariectomy. Endocrinology 2005, 146:503-510.
26. Carroll B.J., Cassidy F., Naftolowitz D., Tatham N.E., Wilson W.H., Iranmanesh A., Liu P.Y., Veldhuis J.D. Pathophysiology of hypercortisolism in depression. Acta Psychiatr. Scand. Suppl. 2007, 90-103.
27. Chantraine A., Nusgens B., Lapiere C.M. Bone remodeling during the development of osteoporosis in paraplegia. Calcif. Tissue Int. 1986, 38:323-327.
28. Chantraine A., van Ouwenaller C., Hachen H.J., Schinas P. Intra-medullary pressure and intra-osseous phlebography in paraplegia. Paraplegia 1979, 17:391-399.
29. Cherruau M., Facchinetti P., Baroukh B., Saffar J.L. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999, 25:545-551.
30. Cherruau M., Morvan F.O., Schirar A., Saffar J.L. Chemical sympathectomy-induced changes in TH-VIP-, and CGRP-immunoreactive fibers in the rat mandible periosteum: influence on bone resorption. J. Cell. Physiol. 2003, 194:341-348.
31. Cizza G., Primma S., Coyle M., Gourgiotis L., Csako G. Depression and osteoporosis: a research synthesis with meta-analysis. Horm. Metab. Res. 2010, 42:467-482.
32. Cizza G., Ravn P., Chrousos G.P., Gold P.W. Depression: a major, unrecognized risk factor for osteoporosis?. Trends Endocrinol. Metab. 2001, 12:198-203.
33. Clowes J.A., Khosla S., Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J. Bone Miner. Res. 2005, 20:1497-1506.
34. de Souza R.L., Pitsillides A.A., Lanyon L.E., Skerry T.M., Chenu C. Sympathetic nervous system does not mediate the load-induced cortical new bone formation. J. Bone Miner. Res. 2005, 20:2159-2168.
35. de Vries F., Souverein P.C., Cooper C., Leufkens H.G., van Staa T.P. Use of β-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif. Tissue Int. 2007, 80:69-75.
36. Dorn L.D., Susman E.J., Pabst S., Huang B., Kalkwarf H., Grimes S. Association of depressive symptoms and anxiety with bone mass and density in ever-smoking and never-smoking adolescent girls. Arch. Pediatr. Adolesc. Med. 2008, 162:1181-1188.
37. Drummond P.D., Finch P.M. Persistence of pain induced by startle and forehead cooling after sympathetic blockade in patients with complex regional pain syndrome. J. Neurol. Neurosurg. Psychiatry 2004, 75:98-102.
38. Ducy P., Amling M., Takeda S., Priemel M., Schilling A., Beil F., Shen J., Vinson C., Rueger J., Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
39. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., Kondo H., Richards W.G., Bannon T.W., Noda M., Clement K., Vaisse C., Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
40. Elloumi M., Courteix D., Sellami S., Tabka Z., Lac G. Bone mineral content and density of Tunisian male rugby players: differences between forwards and backs. Int. J. Sports Med. 2006, 27:351-358.
41. Franchimont N., Wertz S., Malaise M. Interleukin-6: an osteotropic factor influencing bone formation?. Bone 2005, 37:601-606.
42. Frey-Rindova P., de Bruin E.D., Stussi E., Dambacher M.A., Dietz V. Bone mineral density in upper and lower extremities during 12 months after spinal cord injury measured by peripheral quantitative computed tomography. Spinal Cord 2000, 38:26-32.
43. Gage B.F., Birman-Deych E., Radford M.J., Nilasena D.S., Binder E.F. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch. Intern. Med. 2006, 166:241-246.
44. Gerova M., Gero J. The contribution of the left and right sympathetic trunk to control of the diameter of the femoral artery and the consecutive resistant bed. Physiol. Bohemoslov. 1980, 29:503-513.
45. Goldstein D.S., Tack C., Li S.T. Sympathetic innervation and function in reflex sympathetic dystrophy. Ann. Neurol. 2000, 48:49-59.
46. Gu Y., Publicover S.J. Expression of functional metabotropic glutamate receptors in primary cultured rat osteoblasts. Cross-talk with N-methyl-d-aspartate receptors. J. Biol. Chem. 2000, 275:34252-34259.
47. Haug S.R., Brudvik P., Fristad I., Heyeraas K.J. Sympathectomy causes increased root resorption after orthodontic tooth movement in rats: immunohistochemical study. Cell Tissue Res. 2003, 313:167-175.
48. Henry M.J., Pasco J.A., Nicholson G.C., Seeman E., Kotowicz M.A. Prevalence of osteoporosis in Australian women: Geelong osteoporosis study. J. Clin. Densitom. 2000, 3:261-268.
49. Hill E.L., Elde R. Distribution of CGRP-, VIP-, DβH-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 1991, 264:469-480.
50. Hohmann E.L., Elde R.P., Rysavy J.A., Einzig S., Gebhard R.L. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 1986, 232:868-871.
51. Itzstein C., Cheynel H., Burt-Pichat B., Merle B., Espinosa L., Delmas P.D., Chenu C. Molecular identification of NMDA glutamate receptors expressed in bone cells. J. Cell. Biochem. 2001, 82:134-144.
52. Jacka F.N., Pasco J.A., Henry M.J., Kotowicz M.A., Dodd S., Nicholson G.C., Berk M. Depression and bone mineral density in a community sample of perimenopausal women: Geelong osteoporosis study. Menopause 2005, 12:88-91.
53. Janssens K., ten Dijke P., Janssens S., Van Hul W. Transforming growth factor-β1 to the bone. Endocr. Rev. 2005, 26:743-774.
54. Jensen J., Nielsen L.H., Lyhne N., Hallas J., Brosen K., Gram L.F. Drugs and femoral neck fracture: a case-control study. J. Intern. Med. 1991, 229:29-33.
55. Judex S., Gupta S., Rubin C. Regulation of mechanical signals in bone. Orthod. Craniofac. Res. 2009, 12:94-104.
56. Kahl K.G., Greggersen W., Rudolf S., Stoeckelhuber B.M., Bergmann-Koester C.U., Dibbelt L., Schweiger U. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom. Med. 2006, 68:669-674.
57. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 2006, 4:341-348.
58. Kavuncu V., Kuloglu M., Kaya A., Sahin S., Atmaca M., Firidin B. Bone metabolism and bone mineral density in premenopausal women with mild depression. Yonsei Med. J. 2002, 43:101-108.
59. Kim Y., Hamada N., Takahashi Y., Sasaguri K., Tsukinoki K., Onozuka M., Sato S. Cervical sympathectomy causes alveolar bone loss in an experimental rat model. J. Periodontal Res. 2009, 44:695-703.
60. Kimble R.B., Srivastava S., Ross F.P., Matayoshi A., Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 1996, 271:28890-28897.
61. Kinjo M., Setoguchi S., Schneeweiss S., Solomon D.H. Bone mineral density in subjects using central nervous system-active medications. Am. J. Med. 2005, 118:1414.
62. Kiratli B.J., Smith A.E., Nauenberg T., Kallfelz C.F., Perkash I. Bone mineral and geometric changes through the femur with immobilization due to spinal cord injury. J. Rehabil. Res. Dev. 2000, 37:225-233.
63. Klein-Nulend J., Bacabac R.G., Mullender M.G. Mechanobiology of bone tissue. Pathol. Biol. (Paris) 2005, 53:576-580.
64. Kondo H., Nifuji A., Takeda S., Ezura Y., Rittling S.R., Denhardt D.T., Nakashima K., Karsenty G., Noda M. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system. J. Biol. Chem. 2005, 280:30192-30200.
65. Krassioukov A.V., Bunge R.P., Pucket W.R., Bygrave M.A. The changes in human spinal sympathetic preganglionic neurons after spinal cord injury. Spinal Cord 1999, 37:6-13.
66. Kubalek I., Fain O., Paries J., Kettaneh A., Thomas M. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology (Oxford) 2001, 40:1394-1397.
67. Kumar K.K., Tung S., Iqbal J. Bone loss in anorexia nervosa: leptin, serotonin, and the sympathetic nervous system. Ann. N. Y. Acad. Sci. 2010, 1211:51-65.
68. Kurvers H.A. Reflex sympathetic dystrophy: facts and hypotheses. Vasc. Med. 1998, 3:207-214.
69. Kurvers H.A., Jacobs M.J., Beuk R.J., van den Wildenberg F.A., Kitslaar P.J., Slaaf D.W., Reneman R.S. Reflex sympathetic dystrophy: result of autonomic denervation?. Clin. Sci. (Lond.) 1994, 87:663-669.
70. Ladizesky M., Lama M.A., Roldan E.J., Cutrera R.A., Boggio V., Giglio M.J., Cardinali D.P. Effect of unilateral superior cervical ganglionectomy on mandibular bone in rats. Neuro. Endocrinol. Lett. 2003, 24:314-320.
71. Lang T., LeBlanc A., Evans H., Lu Y., Genant H., Yu A. Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J. Bone Miner. Res. 2004, 19:1006-1012.
72. Laroche M., Redon-Dumolard A., Mazieres B., Bernard J. An X-ray absorptiometry study of reflex sympathetic dystrophy syndrome. Rev. Rhum. Engl. Ed. 1997, 64:106-111.
73. Lazo M.G., Shirazi P., Sam M., Giobbie-Hurder A., Blacconiere M.J., Muppidi M. Osteoporosis and risk of fracture in men with spinal cord injury. Spinal Cord 2001, 39:208-214.
74. Levasseur R., Dargent-Molina P., Sabatier J.P., Marcelli C., Breart G. β-Blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l'Osteoporose prospective study. J. Am. Geriatr. Soc. 2005, 53:550-552.
75. Levasseur R., Sabatier J.P., Potrel-Burgot C., Lecoq B., Creveuil C., Marcelli C. Sympathetic nervous system as transmitter of mechanical loading in bone. Joint Bone Spine 2003, 70:515-519.
76. Li J., Ahmad T., Spetea M., Ahmed M., Kreicbergs A. Bone reinnervation after fracture: a study in the rat. J. Bone Miner. Res. 2001, 16:1505-1510.
77. Liu D., Li H., Zhao C.Q., Jiang L.S., Dai L.Y. Changes of substance P-immunoreactive nerve fiber innervation density in the sublesional bones in young growing rats at an early stage after spinal cord injury. Osteoporos. Int. 2008, 19:559-569.
78. Liu D., Zhao C.Q., Li H., Jiang S.D., Jiang L.S., Dai L.Y. Effects of spinal cord injury and hindlimb immobilization on sublesional and supralesional bones in young growing rats. Bone 2008, 43:119-125.
79. Lovejoy J.C. The menopause and obesity. Prim. Care 2003, 30:317-325.
80. Mach D.B., Rogers S.D., Sabino M.C., Luger N.M., Schwei M.J., Pomonis J.D., Keyser C.P., Clohisy D.R., Adams D.J., O'Leary P., Mantyh P.W. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002, 113:155-166.
81. Maimoun L., Couret I., Micallef J.P., Peruchon E., Mariano-Goulart D., Rossi M., Leroux J.L., Ohanna F. Use of bone biochemical markers with dual-energy X-ray absorptiometry for early determination of bone loss in persons with spinal cord injury. Metabolism 2002, 51:958-963.
82. Manelli F., Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol. Metab. 2000, 11:79-85.
83. Marenzana M., De Souza R.L., Chenu C. Blockade of β-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone 2007, 41:206-215.
84. Martin C.D., Jimenez-Andrade J.M., Ghilardi J.R., Mantyh P.W. Organization of a unique net-like meshwork of CGRP+ sensory fibers in the mouse periosteum: implications for the generation and maintenance of bone fracture pain. Neurosci. Lett. 2007, 427:148-152.
85. McClanahan B.S., Ward K.D., Vukadinovich C., Klesges R.C., Chitwood L., Kinzey S.J., Brown S., Frate D. Bone mineral density in triathletes over a competitive season. J. Sports Sci. 2002, 20:463-469.
86. Meisinger C., Heier M., Lang O., Doring A. β-Blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos. Int. 2007, 18:1189-1195.
87. Meller W.H., Zander K.M., Crosby R.D., Tagatz G.E. Luteinizing hormone pulse characteristics in depressed women. Am. J. Psychiatry 1997, 154:1454-1455.
88. Minaire P., Edouard C., Arlot M., Meunier P.J. Marrow changes in paraplegic patients. Calcif. Tissue Int. 1984, 36:338-340.
89. Minkowitz B., Boskey A.L., Lane J.M., Pearlman H.S., Vigorita V.J. Effects of propranolol on bone metabolism in the rat. J. Orthop. Res. 1991, 9:869-875.
90. Misra M., Papakostas G.I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry 2004, 65:1607-1618.
91. Moore R.E., Smith C.K., Bailey C.S., Voelkel E.F., Tashjian A.H. Characterization of β-adrenergic receptors on rat and human osteoblast-like cells and demonstration that β-receptor agonists can stimulate bone resorption in organ culture. Bone Miner. 1993, 23:301-315.
92. Morse L., Teng Y.D., Pham L., Newton K., Yu D., Liao W.L., Kohler T., Muller R., Graves D., Stashenko P., Battaglino R. Spinal cord injury causes rapid osteoclastic resorption and growth plate abnormalities in growing rats (SCI-induced bone loss in growing rats). Osteoporos. Int. 2008, 19:645-652.
93. Munakata M., Kameyama J., Kanazawa M., Nunokawa T., Moriai N., Yoshinaga K. Circadian blood pressure rhythm in patients with higher and lower spinal cord injury: simultaneous evaluation of autonomic nervous activity and physical activity. J. Hypertens. 1997, 15:1745-1749.
94. Mussolino M.E. Depression and hip fracture risk: the NHANES I epidemiologic follow-up study. Public Health Rep. 2005, 120:71-75.
95. Nagata A., Tanaka T., Minezawa A., Poyurovsky M., Mayama T., Suzuki S., Hashimoto N., Yoshida T., Suyama K., Miyata A., Hosokawa H., Nakayama T., Tatsuno I. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells. J. Cell. Physiol. 2009, 221:75-83.
96. Nakamura K. Vitamin D insufficiency in Japanese populations: from the viewpoint of the prevention of osteoporosis. J. Bone Miner. Metab. 2006, 24:1-6.
97. O'Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J. Clin. Psychopharmacol. 2005, 25:26-31.
98. Onyike C.U., Crum R.M., Lee H.B., Lyketsos C.G., Eaton W.W. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 2003, 158:1139-1147.
99. Pagani F., Sibilia V., Cavani F., Ferretti M., Bertoni L., Palumbo C., Lattuada N., De Luca E., Rubinacci A., Guidobono F. Sympathectomy alters bone architecture in adult growing rats. J. Cell. Biochem. 2008, 104:2155-2164.
100. Pasco J.A., Henry M.J., Sanders K.M., Kotowicz M.A., Seeman E., Nicholson G.C. β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J. Bone Miner. Res. 2004, 19:19-24.
101. Petronijevic M., Petronijevic N., Ivkovic M., Stefanovic D., Radonjic N., Glisic B., Ristic G., Damjanovic A., Paunovic V. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone 2008, 42:582-590.
102. Pierroz D., Bouxsein M., Rizzoli R., Ferrari S. Combined treatment with a β-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 2006, 39:260-267.
103. Pierroz D., Muzzin P., Bouxsein M., Rizzoli R., Ferrari S. Mice null for β1β2-adrenergic receptors have low bone mass and architecture and are resistant to isoproterenol-induced inhibition of bone growth. Bone 2005, 36(Suppl):S130.
104. Pierroz D., Muzzin P., Glatt V. β1β2 adrenergic receptor KO mice have decreased total body and cortical bone mass despite increased trabecular number. J. Bone Miner. Res. 2004, 19(Suppl):S32.
105. Ray B.S. Observation on structure and function of the sympathetic nervous system. Med. Bull. (Ann Arbor) 1955, 21:1-12.
106. Reid I.R., Gamble G.D., Grey A.B., Black D.M., Ensrud K.E., Browner W.S., Bauer D.C. β-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J. Bone Miner. Res. 2005, 20:613-618.
107. Rejnmark L., Vestergaard P., Kassem M., Christoffersen B.R., Kolthoff N., Brixen K., Mosekilde L. Fracture risk in perimenopausal women treated with β-blockers. Calcif. Tissue Int. 2004, 75:365-372.
108. Rejnmark L., Vestergaard P., Mosekilde L. Treatment with β-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J. Hypertens. 2006, 24:581-589.
109. Reynolds R.M., Dennison E.M., Walker B.R., Syddall H.E., Wood P.J., Andrew R., Phillips D.I., Cooper C. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif. Tissue Int. 2005, 77:134-138.
110. Richards J.B., Papaioannou A., Adachi J.D., Joseph L., Whitson H.E., Prior J.C., Goltzman D. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med. 2007, 167:188-194.
111. Robins L.N., Helzer J.E., Weissman M.M., Orvaschel H., Gruenberg E., Burke J.D., Regier D.A. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry 1984, 41:949-958.
112. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
113. Rucci N., Rufo A., Alamanou M., Teti A. Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. J. Cell. Biochem. 2007, 100:464-473.
114. Sabo D., Blaich S., Wenz W., Hohmann M., Loew M., Gerner H.J. Osteoporosis in patients with paralysis after spinal cord injury. A cross sectional study in 46 male patients with dual-energy X-ray absorptiometry. Arch. Orthop. Trauma Surg. 2001, 121:75-78.
115. Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of β-blockers and risk of fractures. JAMA 2004, 292:1326-1332.
116. Schmid A., Huonker M., Stahl F., Barturen J.M., Konig D., Heim M., Lehmann M., Keul J. Free plasma catecholamines in spinal cord injured persons with different injury levels at rest and during exercise. J. Auton. Nerv. Syst. 1998, 68:96-100.
117. Schoofs M., Sturkenboom M.C., Leeuwen J.V., Stricker H. Use of β-blockers is associated with BMD and fracture risk. Bone 2005, 36:S129-130.
118. Schweiger U., Weber B., Deuschle M., Heuser I. Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am. J. Psychiatry 2000, 157:118-120.
119. Serhan C.N. Clues for new therapeutics in osteoporosis. N. Engl. J. Med. 2004, 350:1902-1903.
120. Serre C.M., Farlay D., Delmas P.D., Chenu C. Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 1999, 25:623-629.
121. Sosa M., Saavedra P., Mosquera J., Perez-Cano R., Olmos J., Munoz-Torres M., Amerigo M.J., Moro M.J., Diaz-Curiel M., Alegre J., Malouf J., Del Pino J., Nogues X., Torrijos A. β-Blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin. Exp. Res. 2010, (Epub ahead of print).
122. Stanton-Hicks M., Janig W., Hassenbusch S., Haddox J.D., Boas R., Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain 1995, 63:127-133.
123. Suga S., Goto S., Togari A. Demonstration of direct neurite-osteoclastic cell communication in vitro via the adrenergic receptor. J. Pharmacol. Sci. 2010, 112:184-191.
124. Sugiyama T., Price J.S., Lanyon L.E. Functional adaptation to mechanical loading in both cortical and cancellous bone is controlled locally and is confined to the loaded bones. Bone 2010, 46:314-321.
125. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
126. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc. Res. Tech. 2002, 58:77-84.
127. Tran de Q.H., Duong S., Bertini P., Finlayson R.J. Treatment of complex regional pain syndrome: a review of the evidence. Can. J. Anaesth. 2010, 57:149-166.
128. Turker S., Karatosun V., Gunal I. β-Blockers increase bone mineral density. Clin. Orthop. Relat. Res. 2006, 443:73-74.
129. Uebelhart D., Demiaux-Domenech B., Roth M., Chantraine A. Bone metabolism in spinal cord injured individuals and in others who have prolonged immobilisation. A review. Paraplegia 1995, 33:669-673.
130. Varenna M., Zucchi F., Ghiringhelli D., Binelli L., Bevilacqua M., Bettica P., Sinigaglia L. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J. Rheumatol. 2000, 27:1477-1483.
131. Wasner G., Heckmann K., Maier C., Baron R. Vascular abnormalities in acute reflex sympathetic dystrophy (CRPS I): complete inhibition of sympathetic nerve activity with recovery. Arch. Neurol. 1999, 56:613-620.
132. Whooley M.A., Cauley J.A., Zmuda J.M., Haney E.M., Glynn N.W. Depressive symptoms and bone mineral density in older men. J. Geriatr. Psychiatry Neurol. 2004, 17:88-92.
133. Williams L.J., Henry M.J., Berk M., Dodd S., Jacka F.N., Kotowicz M.A., Nicholson G.C., Pasco J.A. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol. 2008, 23:84-87.
134. Wong M.L., Kling M.A., Munson P.J., Listwak S., Licinio J., Prolo P., Karp B., McCutcheon I.E., Geracioti T.D., DeBellis M.D., Rice K.C., Goldstein D.S., Veldhuis J.D., Chrousos G.P., Oldfield E.H., McCann S.M., Gold P.W. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:325-330.
135. Wu Q., Magnus J.H., Liu J., Bencaz A.F., Hentz J.G. Depression and low bone mineral density: a meta-analysis of epidemiologic studies. Osteoporos. Int. 2009, 20:1309-1320.
136. Yan L., Vatner D.E., O'Connor J.P., Ivessa A., Ge H., Chen W., Hirotani S., Ishikawa Y., Sadoshima J., Vatner S.F. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2007, 130:247-258.
137. Yang S., Nguyen N.D., Center J.R., Eisman J.A., Nguyen T.V. Association between β-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2010, (Epub ahead of print).
138. Yazici A.E., Bagis S., Tot S., Sahin G., Yazici K., Erdogan C. Bone mineral density in premenopausal women with major depression. Joint Bone Spine 2005, 72:540-543.
139. Yazici K.M., Akinci A., Sutcu A., Ozcakar L. Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 2003, 117:271-275.
140. Yirmiya R., Bab I. Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol. Psychiatry 2009, 66:423-432.
141. Yirmiya R., Goshen I., Bajayo A., Kreisel T., Feldman S., Tam J., Trembovler V., Csernus V., Shohami E., Bab I. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16876-16881.
142. Zehnder Y., Luthi M., Michel D., Knecht H., Perrelet R., Neto I., Kraenzlin M., Zach G., Lippuner K. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos. Int. 2004, 15:180-189.
143. Zelzer E., Olsen B.R. The genetic basis for skeletal diseases. Nature 2003, 423:343-348.
144. Zhang W., Kanehara M., Zhang Y., Wang X., Ishida T. β-Blocker and other analogous treatments that affect bone mass and sympathetic nerve activity in ovariectomized rats. Am. J. Chin. Med. 2007, 35:89-101.